Atopic dermatitis (AD) is a chronic inflammatory disease of the skin whose main symptom is pruritus and may affect all age ranges. The form of presentation differs depending on this, being the most frequent sign of eczema [1].

Regarding the prevalence, it has been estimated at around 10% of the world population. It also varies according to age group and gender. AD is more common in children (around 10–20%), with males prevailing during this stage, reducing the prevalence rate to 1–5% in adulthood (when it is more frequent around 30 years), where the female sex predominates. In this last age group, this pathology is more severe [1,2], defining it by the use of immunosuppressants or biological agents as the target treatment or by the need for hospitalization due to an outbreak of AD [3,4]. Given the high prevalence, it is important to carry out a rigorous study of this condition, considering the wide variety of comorbidities and their impact on the quality of life of patients who suffer from it.

The clinical presentation of AD in the adult population can vary depending on different criteria such as age, ethnicity, and the underlying biological mechanisms [5].

The disease has three suitably differentiated forms of presentation: (a) a persistent form that begins in childhood and has a chronic-recurrent course until adulthood; (b) a relapsing form, which begins its symptoms in childhood and improves but regresses after a few years free from disease, and (c) a form that begins in adulthood. In a study recently published by Nettis et al., AD appeared for the first time in childhood in 63.3% (if we group both the persistent form and the recurrent form), while 36.7% showed its appearance directly in adulthood [5].

There are different treatments available to control AD, including moisturizers, topical steroids, topical immunomodulators (pimecrolimus, tacrolimus), phototherapy, and systemic immunomodulators when topical therapy or the extension of the disease make their assistance necessary (cyclosporin, methotrexate, mycophenolate mofetil). It is not uncommon for patients to be dissatisfied with their treatment, especially in the moderate and severe forms and precisely in these forms, the portfolio of available drugs will be expanded in the coming years with the inclusion of anti-JAK (Baricitinib, Upadacitinib, and Abrocitinib) and anti-IL drugs (Lebrikizumab, Nemolizumab, Risankizumab, and tralokinumab) apart from already marketed Dupilumab [6].

AD represents a significant physical and psychological burden for both patients and their families. The impact of the disease on the quality of life of patients with AD could be related to its severity [7]. Many of the patients with AD report that the disease limits their daily life, as well as lead them to reduce and avoid social contacts and numerous activities. The feeling of dissatisfaction with life is present in 17% of people with AD, increasing in those who suffer from the most severe form [8]. In the latter, more prevalently, we observed a greater loss of quality-adjusted life years [9]. That is why interventions at the pharmacological and psychotherapeutic levels have favorable results in improving the quality of life of these patients in the treatment of AD and concomitant diseases.

Many concomitant diseases have been associated with AD [3,4,5,6,7,8,9], but the causal relationship between AD and psychological impairment has not been clearly established. It is difficult to decide whether psychological conditions are a direct product of AD or different disorders. Despite this, a relationship between AD with psychological disorders such as anxiety, depression, or even a high risk of suicide has been widely explored [10]. It is important to highlight that not only can AD play a fundamental role in these types of pathologies, but there is a certain relationship between them and atopic diseases in general. A correlation has been observed between atopic pathologies with anxiety and depression in the family context so that the diagnosis of the atopic disease in one of the siblings of the same family should lead us to study the psychological comorbidity both in the diagnosed individual and the whole family [11]. Similarly, not only a qualitative association between AD and psychological disorders has been observed, but the more severe the skin pathology is, the greater the emotional burden may also be [12]. In this way, a medical action that adds a psychological study of these patients is important, as it has been observed that the improvement of AD symptoms leads to a reduction of the emotional burden [13].

When evaluating the concomitance of psychological disorders, the association of AD with sexual dysfunction should also be studied. Male sexual dysfunction is mainly represented by erectile dysfunction (ED). The European Association of Urology defines ED as “the persistent inability to achieve and maintain an erection sufficient to allow satisfactory sexual performance” [14]. The prevalence of ED is high throughout the world, reaching nearly 50% in advanced adulthood, and shares certain risk factors with diseases of a cardiovascular nature. Therefore, erection is a process in which both psychological and neurovascular phenomena converge when studying a possible association with AD since it can present comorbidities in both aspects. Like AD, ED has an important impact on the quality of life of the patient and family [13]. There are numerous ways to measure ED. Without a doubt, questionnaires are the most practical methods for evaluating this condition in daily clinical practice. One of the most widely used is the IIEF-5 (International Index Erectile Function), which classifies ED as mild, mild to moderate, moderate, and severe.

Regarding female sexual dysfunction, the six domains of the female sexual sphere: desire, arousal, lubrication, orgasm, pain, and satisfaction [14]. The DSM-5 establishes a series of criteria to define female sexual dysfunction, based on the previous six domains, defining it as “a lack or reduction of sexual interest or excitement” and this can be manifested by an absence or reduction of interest in sexual activity, decrease in erotic thoughts, reduction of sexual pleasure with sexual activity, or absence or decrease of sensations during sexual encounters [15]. The prevalence is also high, reaching over 40% and becoming higher in postmenopausal women, the most frequent condition in both European and North American women being related to alterations in the sphere of desire, while the prevalence related to alterations in the orgasm dominance drops to around 20–30% [16].

Both female and male sexual dysfunction represent a symptom and not a disease. Additionally, in both population groups, sexuality represents an externalization of well-being on a physical, social, and psychological level. It is, therefore, necessary to rigorously evaluate patients to study possible underlying pathologies and disorders that could be the origin of both ED and female sexual dysfunction [13,14].

Conforming to the literature, more than 30% of patients with AD have significant psychiatric and psychosocial comorbidities [27]. An increased risk of depression and anxiety [11,28,29,30], risk of suicide [31], and sleep disorders [32,33] have been studied and tested using validated questionnaires. However, sexual problem assessment and sexual dysfunction (SD) are usually only insufficiently recorded. Sexual health can markedly affect the quality of life and interpersonal relationships, but it is frequently ignored and undervalued, even more in women [33,34].

Ludwig et al. [35] have recently published a review on the relationship of AD with sexual health. It establishes how AD affects sexual health, quality of life, male and female sexual dysfunction, effects on sexual partners, and how it impacts physical intimacy.

A variety of medical, psychological, and lifestyle factors have been implicated in the etiology of SD. The need for validated measures to diagnose and quantify a complex entity such as SD has led to the generation of numerous scales and self-report questionnaires, some of which focus specifically on the patient’s or partner’s sexual function, whereas others focus on more subjective aspects of well-being or distress related to sexuality [33,34]. A major challenge in the assessment of SD is for the clinician or researcher to select the appropriate questionnaire among a large number of measures available [35]. In this context, studies revealed a serious lack of standardized, internationally acceptable questionnaires that are thoroughly epidemiologically validated in reasonably large, randomized, representative samples and that could be used to assess SD in people with or without a partner and independently of the partner’s gender [36]. These measurements provide useful, quantitative information but don’t cover all aspects of sexual function as currently defined. Another concern of relevance in sexual medicine is the potential to raise socially desirable responses to certain questions [36,37] as well as the discomfort that a physician or patient may feel [34].

The study by Misery et al. [24] suggested that AD considerably affects sexual desire and that the impact of AD is significant for both the patient and the partner. This impact is clearly greater in patients with severe AD and is correlated with those patients who score above 8 on the DLQI. This finding has been endorsed years later in a larger cohort where it relates the severity of AD with the clinical involvement of the genital area and sexual dysfunction [26]. Similarly, one study by Long et al. [38] observed that 19% of AD subjects reported that their sex lives were affected by the disease. Ebata et al., after quantifying serum levels of sexual hormones, concluded that the prevalence of hypogonadism was significantly higher in 40 patients diagnosed with AD than that in age-matched healthy controls. This was evidenced as patients had lower serum levels of testosterone, free testosterone, and higher levels of the luteinizing hormone than controls [39]. Egeberg et al. [18] concluded that there was an independent association between erectile dysfunction (ED) and prior AD based on a case-control study by comparing the risk of prior AD between patients with newly diagnosed ED and matched controls. The systemic inflammation experienced by many of these patients may contribute to endothelial dysfunction, which is central to the pathophysiology of ED. However, Egeberg et al. [17] in 2017 performed a cross-sectional study to estimate the prevalence and odds ratio of erectile dysfunction in patients with AD and found that the prevalence of erectile dysfunction in men with AD was significantly lower, whereas their risk of new-onset erectile dysfunction was not increased compared with the general male population. Unlike the previously mentioned cross-sectional studies, Sampogna established that sexual difficulties are related to young age, high severity, anxiety, and depression [25]. Regarding women, we were not able to identify similar studies with which to compare the results of our patients.

Atopic dermatitis (AD) is just one of the many chronic dermatoses in which there is a significant impact on the sexual life of patients who suffer from it as well as their partners [33]. In the literature, there are studies reporting the effect of psoriasis on sexual function since 1988 [40]. Many studies have associated psoriasis with a significantly increased prevalence and risk of new-onset dysfunction erectile [40,41,42,43,44,45,46]. Of note, psoriasis can alter patients’ body image, resulting in low self-esteem and stigmatization, leading in turn to SD [37]. Similarly, the sexual function seems to be altered in women with psoriasis, although studies are much scarcer in this area [46]. Hidradenitis suppurativa is another inflammatory dermatosis that can be attached to SD. The prevalence of SD in HS was reported in several studies. Overall, compared with healthy controls, patients with HS reported more sexual function problems that contribute to a lower quality of life [47,48,49,50,51,52]. Other cutaneous diseases related to worsening sexual function and reproduction have been lichen simplex [53], vitiligo, and chronic urticaria [54].